BlossomHill Therapeutics stock
BLSMNASDAQBlossomHill Therapeutics, Inc., HealthcareISIN US0951301003
43Score 43 out of 100, Weak
Price and trend
84 / 100
Price history
−7.3% since 2026The chart shows daily closing prices since 7 Aug 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 45% below its 52-week high. Largest decline since 7 Aug 2026: 54% (September 2026 to November 2026).
Chart figures for advanced users
- SMA 50$18.13
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.84
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.35
- The lowest closing price of the last twelve months.
- Resistance$26.82
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BlossomHill Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $431.56M, is number 249 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 43 out of 100 (Weak): rank 497 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $136.68M, financial debt $22.4M.Stability 66
Weaknesses
- Loss-makingLoss of $60.56M over the last 12 months.Fundamentals 10
- Negative free cash flowFree cash flow −$47.99M over the last 12 months.Fundamentals 10
Its standout strength is technical analysis, while profitability and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 36 to 43.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- No date announced.
- Last reported
- 12 Nov 2026EPS reported −$1.29 (expected −$0.93)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$5.540.0%
- Revenue
- $00.0%
- Earnings per share
- −$3.380.0%
- Revenue
- $00.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $39,500 in total.
Not counted: 5 purchases under a fixed plan (compensation, savings plan or a pre-arranged Rule 10b5-1 trading plan).
- Orbimed Advisors Llc, Gordon Carl LPlan purchase
10 Aug 2026, Board
- Shares
- 625,000
- Price
- $16.00
- Value
- $10M
- Schmid John P.Plan purchase
10 Aug 2026, Board
- Shares
- 6,000
- Price
- $16.00
- Value
- $96,000
- Chen BihuaPlan purchase
10 Aug 2026, Board
- Shares
- 312,500
- Price
- $16.00
- Value
- $5M
Show 3 more
- Keyes Jason APlan purchase
10 Aug 2026, Chief Financial Officer
- Shares
- 700
- Price
- $16.00
- Value
- $11,200
- Liptak Vincent PaulPlan purchase
10 Aug 2026, General Counsel
- Shares
- 2,200
- Price
- $16.00
- Value
- $35,200
- Liptak Vincent PaulPurchase
7 Aug 2026, General Counsel
- Shares
- 2,500
- Price
- $15.80
- Value
- $39,500
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at BlossomHill Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Avalo TherapeuticsAVTX $492.07M34
- MiMedx GroupMDXG $484.47M37
- Relmada TherapeuticsRLMD $472.55M38
- Oculis HoldingOCS $469.78M30
- CytomX TherapeuticsCTMX $464.35M31
- Hansa BiopharmaHNSA.ST $458.62M47
- Assembly BiosciencesASMB $455.47M33
- ArvinasARVN $452.5M37
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.